Focus Advisor Solutions LLC boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 178.4% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 4,755 shares of the pharmaceutical company’s stock after acquiring an additional 3,047 shares during the quarter. Focus Advisor Solutions LLC’s holdings in Vertex Pharmaceuticals were worth $2,486,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. MADDEN SECURITIES Corp acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter valued at approximately $26,000. Meeder Asset Management Inc. acquired a new position in Vertex Pharmaceuticals during the second quarter valued at $26,000. Community Financial Services Group LLC acquired a new position in Vertex Pharmaceuticals during the second quarter valued at $26,000. Elevation Wealth Partners LLC boosted its holdings in Vertex Pharmaceuticals by 103.7% in the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 28 shares during the last quarter. Finally, Pingora Partners LLC purchased a new stake in Vertex Pharmaceuticals in the second quarter valued at $32,000. 90.96% of the stock is owned by institutional investors and hedge funds.
Vertex Pharmaceuticals Stock Down 1.1%
VRTX stock opened at $514.75 on Friday. Vertex Pharmaceuticals Incorporated has a 52 week low of $412.27 and a 52 week high of $568.67. The company has a quick ratio of 1.89, a current ratio of 2.34 and a debt-to-equity ratio of 0.17. The firm has a 50-day simple moving average of $522.72 and a 200-day simple moving average of $485.26. The stock has a market capitalization of $130.51 billion, a P/E ratio of 33.12, a P/E/G ratio of 2.73 and a beta of 0.28.
Analyst Ratings Changes
Several equities analysts have recently issued reports on the company. Sanford C. Bernstein raised Vertex Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, July 29th. Jefferies Financial Group boosted their price target on Vertex Pharmaceuticals from $633.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, September 23rd. Rothschild & Co Redburn raised their price objective on shares of Vertex Pharmaceuticals from $570.00 to $580.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Royal Bank Of Canada lifted their target price on shares of Vertex Pharmaceuticals from $576.00 to $600.00 and gave the company an “outperform” rating in a report on Tuesday, November 3rd. Finally, Wall Street Zen cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, October 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $596.44.
Read Our Latest Report on VRTX
Insider Buying and Selling
In other Vertex Pharmaceuticals news, Director Sangeeta Bhatia sold 271 shares of Vertex Pharmaceuticals stock in a transaction on Monday, November 16th. The shares were sold at an average price of $547.86, for a total transaction of $148,470.06. Following the sale, the director owned 4,653 shares of the company’s stock, valued at $2,549,192.58. The trade was a 5.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy Thornberry sold 1,000 shares of the company’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $547.86, for a total transaction of $547,860.00. Following the sale, the director directly owned 1,109 shares of the company’s stock, valued at $607,576.74. The trade was a 47.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 16,557 shares of company stock worth $9,071,071. 0.20% of the stock is owned by corporate insiders.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
